Cancel
Known information
- CEO of Aliada Therapeutics
- Serves on other private company boards including Sionna Therapeutics and is Chair of Ambagon Therapeutics
- Was a Venture Partner at Carnot Pharma (RA Ventures)
- Previously President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019
- Has 20+ years of industry experience in building healthcare and technology companies
- Co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies
- Co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company
- Has led and advised companies in diverse areas such as digital health, materials, and diagnostics
- Served as Director on the board of multiple venture-backed companies
- Advisor and investor in 'A Late Quartet', a feature film centered on a cellist diagnosed with Parkinson’s disease
- Received his JD from the University of Virginia School of Law
- Received his BA from Whittier College
About Eliem Therapeutics
Eliem Therapeutics is a biopharmaceutical company focused on developing therapies for neuronal excitability disorders, with key projects including ETX-155 for major depressive disorder and focal onset seizures.
Report inaccurate information
